Biomarker development in the precision medicine era: lung cancer as a case study
AJ Vargas, CC Harris - Nature reviews cancer, 2016 - nature.com
Precision medicine relies on validated biomarkers with which to better classify patients by
their probable disease risk, prognosis and/or response to treatment. Although …
their probable disease risk, prognosis and/or response to treatment. Although …
The hallmarks of premalignant conditions: a molecular basis for cancer prevention
BM Ryan, JM Faupel-Badger - Seminars in oncology, 2016 - Elsevier
The hallmarks of premalignant lesions were first described in the 1970s, a time when
relatively little was known about the molecular underpinnings of cancer. Yet it was clear …
relatively little was known about the molecular underpinnings of cancer. Yet it was clear …
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
M Andrea, T Weinschenk, V Goldfinger… - US Patent …, 2019 - Google Patents
The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the immuno …
immunotherapeutic methods. In particular, the present invention relates to the immuno …
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
M Andrea, T Weinschenk, V Goldfinger… - US Patent …, 2019 - Google Patents
The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the immuno …
immunotherapeutic methods. In particular, the present invention relates to the immuno …
[HTML][HTML] An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers
Introduction: Up to 30% stage I lung cancer patients suffer recurrence within 5 years of
curative surgery. We sought to improve existing protein-coding gene and microRNA …
curative surgery. We sought to improve existing protein-coding gene and microRNA …
Denoising autoencoder, a deep learning algorithm, aids the identification of a novel molecular signature of lung adenocarcinoma
Precise biomarker development is a key step in disease management. However, most of the
published biomarkers were derived from a relatively small number of samples with …
published biomarkers were derived from a relatively small number of samples with …
Integration of multiple “OMIC” biomarkers: A precision medicine strategy for lung cancer
AI Robles, CC Harris - Lung Cancer, 2017 - Elsevier
More than half of all new lung cancer diagnoses are made in patients with locally advanced
or metastatic disease, at which point therapeutic options are scarce. It is anticipated …
or metastatic disease, at which point therapeutic options are scarce. It is anticipated …
The prognostic potential of alternative transcript isoforms across human tumors
Background Phenotypic changes during cancer progression are associated with alterations
in gene expression, which can be exploited to build molecular signatures for tumor stage …
in gene expression, which can be exploited to build molecular signatures for tumor stage …
[HTML][HTML] Liquid biopsy in early stage lung cancer
Lung cancer is the leading cause of cancer-associated deaths worldwide. Surgery is the
standard treatment for early-stage non-small cell lung cancer (NSCLC). However, 30% to …
standard treatment for early-stage non-small cell lung cancer (NSCLC). However, 30% to …
[HTML][HTML] Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I–III lung adenocarcinoma
Y Zhang, Z Yang, Y Tang, C Guo, D Lin, L Cheng… - Genes & …, 2023 - Elsevier
The high risk of postoperative mortality in lung adenocarcinoma (LUAD) patients is
principally driven by cancer recurrence and low response rates to adjuvant treatment. Here …
principally driven by cancer recurrence and low response rates to adjuvant treatment. Here …